- GQ Magazine Pays Tribute to America's Top Research Scientists -
- Also Featured Jeffrey Cummings, Chair of Prana's Biotechnology Research & Development Advisory Board -
MELBOURNE, Australia, May 18 /PRNewswire/ -- Dr. Rudy Tanzi, Prana Biotechnology's (Nasdaq: PRAN) Co-Founding Scientist and the Director of the Genetics and Aging Research Unit at the MassGeneral Institute for Neurodegenerative Diseases, will be featured in a six-page photo spread, in the June issue of GQ Magazine. Rudy and other researchers, who have played a vital role in the development of treatments for diseases such as cancer, HIV and Alzheimer's disease, are pictured along celebrated artists Sheryl Crow, Josh Groban, Will.i.am, Joe Perry, and Seal.
The spread is part of the "Rock Stars of Science" campaign, a philanthropic project launched by GQ Magazine and the Geoffrey Beene Gives Back intuitive, to raise awareness for the need of future research funding.
"If we can get medical research the same attention as a great rock band like Aerosmith, just think about how much faster we will be able to raise the funds needed to cure diseases like Alzheimer's," commented Dr. Tanzi.
One of three prominent Alzheimer researchers featured, Dr. Tanzi has been instrumental in the quest for developing a cure to the disease. He has identified and characterized several different AD genes, including the first Alzheimer's disease gene, the beta-amyloid protein precursor (APP) and has received several awards for his work including the two highest awards for Alzheimer's disease research: The Metropolitan Life Foundation Award and The Potamkin Prize.
Dr. Tanzi is also a co-founder of the "Metal hypothesis of Alzheimer's disease," the premise behind Prana's novel therapeutics for treating the disease.
Also featured in the magazine is Professor Jeffrey L. Cummings, the Chair of Prana Biotechnology Research & Development Advisory Board. A world renowned authority on Alzheimer's disease Dr. Cummings' has authored 30 books and over 500 peer reviewed papers on the disease.
"We congratulate Professor Tanzi and Professor Cummings for their rock star achievements," said Geoffrey Kempler, Prana's Chairman and CEO. "We consider it a significant accomplishment that some of the most brilliant scientific minds are leading advocates of Prana and its strategy for the treatment of Alzheimer's disease."
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The
* For further information, and descriptions of the peer-reviewed journals, please visit the Company's web site at www.pranabio.com.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on From 20-F and its reports on Form 6-K. Such statements are based on management's current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.
|SOURCE Prana Biotechnology Limited|
Copyright©2009 PR Newswire.
All rights reserved